JP7579636B2 - 膵がん治療のための組み合わせ治療薬 - Google Patents

膵がん治療のための組み合わせ治療薬 Download PDF

Info

Publication number
JP7579636B2
JP7579636B2 JP2019510651A JP2019510651A JP7579636B2 JP 7579636 B2 JP7579636 B2 JP 7579636B2 JP 2019510651 A JP2019510651 A JP 2019510651A JP 2019510651 A JP2019510651 A JP 2019510651A JP 7579636 B2 JP7579636 B2 JP 7579636B2
Authority
JP
Japan
Prior art keywords
pharma
cobimetinib
acceptable salt
combination
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526559A5 (enExample
JP2019526559A (ja
Inventor
セトルマン，ジェフ
サフ，ニセビータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2019526559A publication Critical patent/JP2019526559A/ja
Publication of JP2019526559A5 publication Critical patent/JP2019526559A5/ja
Priority to JP2024125935A priority Critical patent/JP2024170398A/ja
Application granted granted Critical
Publication of JP7579636B2 publication Critical patent/JP7579636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019510651A 2016-08-23 2017-08-22 膵がん治療のための組み合わせ治療薬 Active JP7579636B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125935A JP2024170398A (ja) 2016-08-23 2024-08-01 膵がん治療のための組み合わせ治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378322P 2016-08-23 2016-08-23
US62/378,322 2016-08-23
PCT/US2017/047985 WO2018039211A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125935A Division JP2024170398A (ja) 2016-08-23 2024-08-01 膵がん治療のための組み合わせ治療薬

Publications (3)

Publication Number Publication Date
JP2019526559A JP2019526559A (ja) 2019-09-19
JP2019526559A5 JP2019526559A5 (enExample) 2020-10-01
JP7579636B2 true JP7579636B2 (ja) 2024-11-08

Family

ID=59762090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510651A Active JP7579636B2 (ja) 2016-08-23 2017-08-22 膵がん治療のための組み合わせ治療薬
JP2024125935A Pending JP2024170398A (ja) 2016-08-23 2024-08-01 膵がん治療のための組み合わせ治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125935A Pending JP2024170398A (ja) 2016-08-23 2024-08-01 膵がん治療のための組み合わせ治療薬

Country Status (11)

Country Link
US (2) US10933058B2 (enExample)
EP (1) EP3503922B1 (enExample)
JP (2) JP7579636B2 (enExample)
KR (1) KR20190039951A (enExample)
CN (1) CN109641058A (enExample)
AU (1) AU2017316618A1 (enExample)
BR (1) BR112019002945A2 (enExample)
CA (1) CA3034259A1 (enExample)
IL (1) IL264589A (enExample)
MX (1) MX2019002121A (enExample)
WO (1) WO2018039211A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3503922B1 (en) * 2016-08-23 2022-10-26 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer
WO2020014650A1 (en) * 2018-07-13 2020-01-16 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
IL292448A (en) * 2019-10-22 2022-06-01 Chemistryrx Preparations containing an oncokinase suppressor for use in the treatment of congenital hyperplasia of the epidermis and skin
CN115243719B (zh) * 2020-03-06 2024-09-13 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用
CN116509852A (zh) * 2023-04-30 2023-08-01 兰州大学第二医院 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
EP3503922B1 (en) * 2016-08-23 2022-10-26 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ＢＭＣ Ｃａｎｃｅｒ、（２０１０）、１０、５１５
Ｃａｎｃｅｒ Ｃｅｌｌ、（２０１４）、２６、２０７－２２１
Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ、（２０１５）、７５（６）、１０９１－１１０１
Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｌｏｇｙ、（２０１４）、４２、２８２－２９３
Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ、（２０１５）、１４（１）、４０－４７
Ｎａｔｕｒｅ、（２０１６．０６）、５３４、６４７－６５１
Ｏｎｃｏｔａｒｇｅｔ、（２０１５）、６（１６）、１４４７２－１４４８７
ＰＬＯＳ Ｏｎｅ、（２０１３）、８（１９）、ｅ７６５５１

Also Published As

Publication number Publication date
MX2019002121A (es) 2019-08-12
JP2024170398A (ja) 2024-12-10
CA3034259A1 (en) 2018-03-01
JP2019526559A (ja) 2019-09-19
CN109641058A (zh) 2019-04-16
US20190175576A1 (en) 2019-06-13
KR20190039951A (ko) 2019-04-16
US20210283120A1 (en) 2021-09-16
US10933058B2 (en) 2021-03-02
US12419879B2 (en) 2025-09-23
EP3503922B1 (en) 2022-10-26
BR112019002945A2 (pt) 2019-05-21
AU2017316618A1 (en) 2019-02-07
EP3503922A1 (en) 2019-07-03
IL264589A (en) 2019-02-28
WO2018039211A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
Yan et al. Aurora‐A kinase: a potent oncogene and target for cancer therapy
Herishanu et al. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications
ES3033810T3 (en) Cancer treatments using combinations of cdk and erk inhibitors
Verma et al. Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis
AU2014368916B2 (en) Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
Drappatz et al. Therapeutic strategies for inhibiting invasion in glioblastoma
Zhao et al. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
US20240108628A1 (en) Combination therapy with mek inhibitor and cdk4/6 inhibitor to treat pancreatic cancer
Ferté et al. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
JP2022044767A (ja) 癌を処置する方法
US20140348819A1 (en) Methods of Treating Cancer
Fahrenholtz et al. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts
Sahu et al. Cotargeting of MEK and PDGFR/STAT3 pathways to treat pancreatic ductal adenocarcinoma
AU2016297555A1 (en) Methods for treating cancer using apilimod
Zhang et al. SEMA3C supports pancreatic cancer progression by regulating the autophagy process and tumor immune microenvironment
CA2995586A1 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
KR20200083532A (ko) 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
Langdon et al. Combinatorial screening of pancreatic adenocarcinoma reveals sensitivity to drug combinations including bromodomain inhibitor plus neddylation inhibitor
KR20230026493A (ko) Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법
JP7762796B2 (ja) Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
Saleh et al. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
US20150306216A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
HK40001148A (en) Combination therapy for the treatment of pancreatic cancer
Pan et al. STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220627

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220714

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220715

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220805

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241028

R150 Certificate of patent or registration of utility model

Ref document number: 7579636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150